To the best of our knowledge, this is the first study reporting a gypsogenin-derived anti-glioma agent (compound 10) exerting cytotoxic activity through the induction of apoptosis and the inhibition of EGFR. The gene discussed is EGFR; the disease is central nervous system cancer.